Erasing iatrogenic neoantigens from in vivo CRISPR screens
- PMID: 33691131
- DOI: 10.1016/j.immuni.2021.02.017
Erasing iatrogenic neoantigens from in vivo CRISPR screens
Abstract
In vivo genetic screens using CRISPR-Cas9 are a powerful tool to resolve the molecular determinants of response and resistance to cancer immunotherapies; however, vector immunogenicity can introduce artifact. In this issue of Immunity, Dubrot et al. report a strategy to "erase" vector-associated neoantigens, enabling a more physiologic assessment of tumor-immune cell interactions in immunocompetent hosts.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests F.Y. and C.A.K. hold provisional patents related to cell and gene therapy unrelated to the current work. C.A.K. is a scientific advisor to the following immunotherapy-focused companies: Achilles Therapeutics, Aleta Biotherapeutics, Bellicum Pharmaceuticals, Catamaran Biotherapeutics, Obsidian Therapeutics, Roche/Genentech, Pact Biopharma, T-Knife.
Comment on
-
In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.Immunity. 2021 Mar 9;54(3):571-585.e6. doi: 10.1016/j.immuni.2021.01.001. Epub 2021 Jan 25. Immunity. 2021. PMID: 33497609
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical